Thus, the ability of murepavadin to exploit MC’s immunomodulatory functions could form the basis for the treatment of skin infection caused by bacterial species such as P. aeruginosa and S. aureus. Furthermore, the findings presented herein that MCs expressing missense MRGPRX2 variants G165E (rs141744602) and V282M (rs779414608) were resistant to murepavadin-induced degranulation likely has important clinical implications. This evidence concerns the gene MRGPRX2 and skin infection.